Edition:
United States

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

20.22USD
13 Jan 2017
Change (% chg)

$0.38 (+1.92%)
Prev Close
$19.84
Open
$19.86
Day's High
$20.69
Day's Low
$19.57
Volume
111,618
Avg. Vol
101,856
52-wk High
$33.30
52-wk Low
$14.85

MGNX.OQ

Chart for MGNX.OQ

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer,... (more)

Overall

Beta: --
Market Cap(Mil.): $704.38
Shares Outstanding(Mil.): 34.84
Dividend: --
Yield (%): --

Financials

  MGNX.OQ Industry Sector
P/E (TTM): -- 46.47 30.92
EPS (TTM): -1.56 -- --
ROI: -15.36 -0.87 14.82
ROE: -16.33 -0.56 16.24

BRIEF-Macrogenics files for potential mixed shelf offering

* Files for potential mixed shelf offering; size not disclosed - SEC filing Source text: [http://bit.ly/2eBbLcf] Further company coverage:

Nov 02 2016

BRIEF-Macrogenics Qtrly loss per share $0.97

* Q3 earnings per share view $-0.80, revenue view $12.5 million -- Thomson Reuters I/B/E/S

Nov 02 2016

BRIEF-Takeda and Macrogenics announce conclusion of MGD010 license and option agreement

* Takeda and Macrogenics announce the conclusion of their MGD010 license and option agreement

Sep 12 2016

BRIEF-Macrogenics says on track for three new IND submissions in 2016-2017

* Macrogenics provides update on corporate progress and second quarter 2016 financial results

Aug 03 2016

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF237.40 -1.60
Roche Holding Ltd. (RO.S) CHF241.80 -1.60
Amgen, Inc. (AMGN.OQ) $156.12 +0.76
Xencor Inc (XNCR.OQ) $26.16 +0.41

Earnings vs. Estimates